m-chlorophenylpiperazine
Small moleculeexperimental
meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as "ecstasy" in Europe and the United States. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00605904)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 4 (5-HT4) receptorAGONIST
HTR4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMeta-Chlorophenylpiperazine ↗
Also known as
- 1-(3-chlorophenyl)piperazine
- 1-(3-chlorophenyl)piperazine dihydrochloride
- 1-(3-chlorophenyl)piperazine monohydrochloride
- 1-3-cpp
- 1-(m-chlorophenyl)piperazine
- 3-chlorophenylpiperazine
- dihydrochloro phenyl piperazine
- m-chlorophenylpiperazine
- m-chlorophenylpiperazine
- m-cpp
- meta-chlorophenylpiperazine
- meta-chlorophenylpiperazine
- meta-chlorophenylpiperazine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03962829 | N/A | Feb 1, 2019 | University of Birmingham |
| NCT00605904 | Phase 2 | Jan 1, 2008 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2008 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2008 |
| University of Birmingham | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1